BIAFBioAffinity Technologies Inc
$1.63
$0.11
(7.24%)
Closed $1.63
$0.0178
(1.09%)
After Hours
Reported EarningsMay 8
Mkt Cap$6.89M
Vol133,975.00
Fundamentals
Mkt Cap
$6.89M
Volume
-
52W High
$13.80
52W Low
$0.693
PE Ratio
-0.14
Avg. Volume
211,932.48
EPS (Annual)
-$8.66
Rev/Employee
$108,104.54
Earnings
May 08
48
Neutral Sentiment
How do you feel about BIAF?
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced the Society for Advanced Bronchoscopy (SAB) will host a webinar on CyPath Lungs expanding role in pulmonary, oncology and surgical...
Business Wire
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath Lung Technology
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the Mexican Institute of...
Business Wire
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung
bioAffinity posts softer first-quarter 2026 results after exiting lower-margin pathology services, though CyPath Lung adoption and clinical-trial progress gain traction.
Zacks
bioAffinity Technologies Reports Record Monthly CyPath Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath Lung...
Business Wire
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath Lung
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases...
Business Wire
bioAffinity Technologies Launches New Study To Expand Use of CyPath Lung Technology for Asthma and COPD Diagnosis and Treatment
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a pilot study with Brooke Army...
Business Wire
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
Zacks
New Case Study: bioAffinity Technologies CyPath Lung Diagnostic Supports Physicians Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study...
Business Wire
bioAffinity Technologies CyPath Lung to Be Featured at Cleveland Clinic Annual Advances in Early Lung Cancer Detection Symposium April 16
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, announces that its CyPath Lung test will be featured at...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest BIAF News
ViewMultidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
Business Wire
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath Lung Technology
Business Wire
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung
Zacks
Advertisement|Remove ads.